Vascularization of Thick Tissue Constructs for Regenerative Medicine

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-19-C-0045
Agency Tracking Number: A2-7484
Amount: $503,939.06
Phase: Phase II
Program: SBIR
Solicitation Topic Code: A17-068
Solicitation Number: 2017.1
Timeline
Solicitation Year: 2017
Award Year: 2019
Award Start Date (Proposal Award Date): 2019-05-13
Award End Date (Contract End Date): 2020-05-12
Small Business Information
701 McMillian Way NW, Huntsville, AL, 35806
DUNS: 185169620
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 Prabhakar Pandian
 (205) 726-4800
 proposals-contracts@cfdrc.com
Business Contact
 Tanu Singhal
Phone: (256) 726-4924
Email: tanu.singhal@cfdrc.com
Research Institution
N/A
Abstract
Lack of ability to develop vascularized thick tissue constructs is a major limitation for use in tissue repair and regeneration in humans. A key bottleneck, of particular relevance to thick tissues (>1cm) is the mass transfer limitations across the vasculature to the tissue cells, which detrimentally impacts the long term viability and functionality of the tissue constructs.In this context, the overall goal of this project is to develop and demonstrate a novel platform for generation of vascularized thick tissue constructs that mimic the desired cell, tissue and organ architecture. During Phase I, we demonstrated critical proof-of-concept using a synergistic in silico and in vitro approach to guide the development of the thick vascularized tissues. Viability, biomarker and functionality analyses were performed to experimentally demonstrate thick tissue vascularization strategies. In Phase II, we will extended the approach to multiple tissue types (cardiac and liver), including characterization of the tissue constructs by functional assays and long term maintenance up to 30 days. The developed constructs will be validated against in vivo data for both structural and functional responses. Technology insertion and commercialization activities will be pursued including beyond Phase II initiatives, such as FDA regulatory approval and partnerships for manufacturing scale-up.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government